skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
;  [1];  [2];  [3]; ;  [2];  [1];  [4]
  1. Department of Radiation Oncology, New York University School of Medicine, New York, New York (United States)
  2. Department of Surgery, New York University School of Medicine, New York, New York (United States)
  3. Department of Medical Oncology, New York University School of Medicine, New York, New York (United States)
  4. Department of Population Health, New York University School of Medicine, New York, New York (United States)

Purpose: To report the 5-year results of a technique of prone breast radiation therapy delivered by a regimen of accelerated intensity modulated radiation therapy with a concurrent boost to the tumor bed. Methods and Materials: Between 2003 and 2006, 404 patients with stage I-II breast cancer were prospectively enrolled into 2 consecutive protocols, institutional trials 03-30 and 05-181, that used the same regimen of 40.5 Gy/15 fractions delivered to the index breast over 3 weeks, with a concomitant daily boost to the tumor bed of 0.5 Gy (total dose 48 Gy). All patients were treated after segmental mastectomy and had negative margins and nodal assessment. Patients were set up prone: only if lung or heart volumes were in the field was a supine setup attempted and chosen if found to better spare these organs. Results: Ninety-two percent of patients were treated prone, 8% supine. Seventy-two percent had stage I, 28% stage II invasive breast cancer. In-field lung volume ranged from 0 to 228.27 cm{sup 3}, mean 19.65 cm{sup 3}. In-field heart volume for left breast cancer patients ranged from 0 to 21.24 cm{sup 3}, mean 1.59 cm{sup 3}. There was no heart in the field for right breast cancer patients. At a median follow-up of 5 years, the 5-year cumulative incidence of isolated ipsilateral breast tumor recurrence was 0.82% (95% confidence interval [CI] 0.65%-1.04%). The 5-year cumulative incidence of regional recurrence was 0.53% (95% CI 0.41%-0.69%), and the 5-year overall cumulative death rate was 1.28% (95% CI 0.48%-3.38%). Eighty-two percent (95% CI 77%-85%) of patients judged their final cosmetic result as excellent/good. Conclusions: Prone accelerated intensity modulated radiation therapy with a concomitant boost results in excellent local control and optimal sparing of heart and lung, with good cosmesis. Radiation Therapy Oncology Group protocol 1005, a phase 3, multi-institutional, randomized trial is ongoing and is evaluating the equivalence of a similar dose and fractionation approach to standard 6-week radiation therapy with a sequential boost.

OSTI ID:
22420377
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 89, Issue 4; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed
Journal Article · Wed Jun 01 00:00:00 EDT 2016 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22420377

Conservative surgery and radiotherapy for stage I/II breast cancer using lung density correction: 10-year and 15-year results
Journal Article · Fri Apr 01 00:00:00 EST 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22420377

Long-term Clinical Outcomes of Whole-Breast Irradiation Delivered in the Prone Position
Journal Article · Tue May 01 00:00:00 EDT 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22420377